The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

Results from the DREAMM-7 Phase III trial demonstrated that Blenrep (belantamab mafodotin) combined with bortezomib and dexamethasone significantly improved overall survival, progression-free survival ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in 2022. The U.K.’s Medicines and Healthcare products Regulatory Agency ...

Phase III DREAMM-7 trial data show that the combination of Blenrep (belantamab mafodotin) with bortezomib and dexamethasone (BorDex) significantly improved overall survival in patients with relapsed ...

A case analysis provides a new understanding of the ocular side effects of Blenrep, an antibody drug conjugate that is being reviewed by the FDA as a combination treatment for patients with multiple ...

GSK’s Blenrep (belantamab mafodotin) combinations have been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat multiple myeloma in adults. The drug has been authorised ...

UK approval first in the world with submissions under review in 14 markets and additional approvals expected in 2025 Blenrep is an ADC comprising a humanised BCMA monoclonal antibody conjugated to the ...

Second major approval for Blenrep combinations, with more expected in 2025 This is the second major regulatory approval for Blenrep combinations for the treatment of relapsed or refractory multiple ...

LONDON (dpa-AFX) - British drug maker GSK plc (GSK.L, GSK) announced Monday the approval of Blenrep combinations by Japan's Ministry of Health, Labour and Welfare or MHLW for the treatment of ...

Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials Trials showed significant progression-free survival benefit and positive overall survival trends for Blenrep ...

Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending approval for the Blenrep (belantamab mafodotin) combination therapy to treat relapsed or refractory ...

— We have everything you need: full data on over 900 000 bonds, 80 000 stocks, 116 000 ETF & Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & ...